Compare Abeona Therapeutics Inc (ABEO) vs Coursera Inc (COUR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Coursera Inc — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Coursera Inc trades at $5.87 (market cap $1.66B). The key difference: Coursera Inc is far larger — about 4.4× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Coursera Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | COUR | |
|---|---|---|
Market Cap | $373.32M | $1.66B |
Sector | Health | Consumer Staples |
52-Week High | $7.23 | $12.70 |
52-Week Low | $4.17 | $5.09 |
Enterprise Value | $228.22M | $915.98M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Coursera (COUR) trades at $5.80, down 1.69% today, with a bullish technical signal from moving averages. Revenue grew to $757.5M in 2025, though net income remains negative at -$51M. The company completed its merger with Udemy in May 2026, aiming for synergies, and announced a $500M share repurchase program. Positive cash flow from operations of $108.7M supports financial stability.
The outlook is mixed: analyst consensus targets $8.00 (37.9% upside), with 53% buy ratings, but persistent losses and competitive pressures pose risks. Earnings misses in recent quarters highlight execution challenges. The stock offers growth potential via market expansion and merger benefits, yet profitability concerns and market volatility require cautious evaluation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Coursera Inc
Coursera Inc is a global online learning platform that offers anyone, anywhere access to online courses and degrees from world-class universities and companies. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The platform will contain a catalog of high-quality content and credentials, content developed by leading university and industry partners, data and machine learning drive personalized Learning, effective marketing, and skills Benchmarking and others.
Read more on COUR →
